Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension
Marks Lupin’s Debut in the Chinese Market MUMBAI, India and BEIJING and NAPLES, Fla., May 22, 2026 /PRNewswire/ — Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that China’s National Medical Products Administration has approved its Abbreviated New Drug Application for Oseltamivir Phosphate, in partnership with Yabao Pharmaceuticals,…